GKSL Fined ₹10,000 Each by NSE & BSE for Delayed Board Meeting Intimation
Gujarat Kidney And Super Speciality Limited (GKSL) was fined ₹10,000 each by NSE and BSE for delayed board meeting intimation. The company will pay the fines within the stipulated timelines. No impact on financial or operational activities is expected.
The fines are relatively small (₹10,000 each) and the company explicitly states there is no impact on its financial, operational, or other activities, limiting the overall impact.
The announcement details regulatory non-compliance leading to fines, which is a negative event. However, the fines are small and the company states there is no impact on its operations or financials, and it will comply with payment timelines, balancing the negativity.
Gujarat Kidney And Super Speciality Limited (GKSL) has received notices from both the National Stock Exchange of India Limited (NSE) and BSE Limited, imposing a fine of ₹10,000 each (including GST) on the company. The fines are a consequence of the company's failure to provide prior intimation regarding a Board of Directors meeting, as required by Regulation 29 (2)/29(3) of the SEBI (LODR) Regulations, 2015.
The company has stated that it will make the payment of these fines within the timelines prescribed by both exchanges.
GKSL has further clarified that the levy of these fines will not have any impact on the financial, operational, or other activities of the company. The company received these communications from NSE and BSE on 15th April 2026, with the violation pertaining to the delay in furnishing prior intimation about the board meeting.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.